Smith & Nephew (SNN) Stock Analysis & Winston Score
Smith & Nephew is a British medical device company that makes products used by surgeons and doctors to repair and replace damaged body parts. Its three main business areas are orthopedics (knee and hip replacements), sports medicine and joint repair (tools to fix torn ligaments and cartilage), and advanced wound management (bandages and dressings for hard-to-heal wounds). Hospitals, surgeons, and healthcare systems around the world are its main customers. The company earns money by selling its devices and consumable products directly to hospitals, with recurring revenue coming from the ongoing need for wound care supplies and surgical tools. Smith & Nephew operates globally, with significant revenue from the US, Europe, and emerging markets, and generates roughly $5 billion in annual revenue. Its competitive position relies on strong surgeon relationships and a broad product portfolio, but it faces pressure from larger rivals like Stryker and Zimmer Biomet, and improving its operational efficiency remains a key challenge for sustaining growth.
Winston Score: 59/100 — Good
A decent business — some strong pillars, some weaker.
- Quality: Good (16/30)
- Growth: Exceptional (17/20)
- Cash Flow: Exceptional (9/10)
- Stability: Strong (7/10)
- Valuation: Strong (7/10)
- Ownership: Weak (1/15)
Key Facts
Price: $30.43
Market Cap: $12.8B
Sector: Healthcare
Industry: Medical - Devices
Exchange: New York Stock Exchange

